动物造模,心脏肥大,异丙肾上腺素 z-bio 2021-02-19 308

　　Objective: To find important biomarkers through serum metabolomics to study the cause of myocardial hypertrophy in rats.

　　Method: The rat cardiac hypertrophy model was established by intraperitoneal injection of 30 mg/(kg·D) isoproterenol for 30 consecutive days. The cardiac mass index was used to evaluate the rat cardiac hypertrophy model. Ultra performance liquid chromatography detects the endogenous metabolites of quadrupole time-of-flight mass spectrometry in rat serum, uses MPP software and the human metabolome database (HMDB) database to analyze the differences of biotransformants, and uses MetaboAnalyst 4.0 to determine biomarkers And analyze metabolic pathways.

　　Result: Intraperitoneal injection of isoproterenol can induce cardiac hypertrophy in rats. There are significant differences between the serum biotransformants between the cardiac hypertrophy model group and the normal group, and a total of 10 potential biomarkers have been identified. Compared with the normal group, Sphingosine-1-phosphate and Dihomo-γ-linolenic acid in the cardiac hypertrophy model group were significantly down-regulated, among which D-fructose-1,6-diphosphate, deoxyadenosine and N.-acetylmethionine Acid, phytosphingosine, allantoin, 3-keto-β-D-galactose, octane number and glycerol were all significantly up-regulated.

　　 Conclusion: Isoprene-induced cardiac hypertrophy includes metabolic pathways, such as sphingolipid metabolism, glycerolipid metabolism, galactose metabolism, unsaturated fatty acid biosynthesis and purine metabolism. This study provides a reference for revealing the changes in circulating blood metabolism in cardiac hypertrophy induced by isoproterenol.